Observational Disease Registry of Patients Treated with Systemic Mold-Active Triazoles
This study seeks to describe representative real-world patterns of
care for the management of invasive fungal infections (IFIs),
including invasive mold infection (IMI). Specifically, the study
goals are to examine real world patient characteristics and
treatment patterns, associated healthcare resource utilization, and
outcomes associated with use of mold-active triazoles (MATs) to
treat IFIs.
Study phase (if other): Registry
Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.
Patients must meet both of the following inclusion criteria:
1. Initiating one of the following target drugs: ISAV, VORI, POSA. Patients may be enrolled within 60 days from the time of treatment initiation.
2. Patient or legal representative has provided the appropriate consent and/or release to access medical records.
Primary disease category: HIV/AIDS & Infectious Disease
Sponsor: Astellas Pharma Global Development, Inc.
Projected enrollment dates: November 2016 to September 2020
Official study title: Observational Disease Registry of Patients Treated with Systemic Mold-Active Triazoles